EGFR and neoplasm: The high EGFR expression found in ovarian tumors [8] and known ability of this pathway to drive tumor cell proliferation and dissemination remain compelling reasons to continue to pursue EGFR inhibitors for ovarian cancer therapy, yet the poor results seen in clinical trials to date point to a need for better methods for patient selection and stratification.